Active substanceDextran [cf.m.m.mass 50,000-70000]Dextran [cf.m.m.mass 50,000-70000]
Similar drugsTo uncover
  • Polyglukin
    solution d / infusion 
    MOSFARM, OJSC     Russia
  • Polyglukin
    solution d / infusion 
  • Polyglukin
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Polyglukin
    solution d / infusion 
    MAKSFARM, OJSC     Russia
  • Dosage form: & nbspsolution for infusions
    Composition:

    Active substance: dextran [cf. Mol. weight 50,000-70000] 60 g;

    Excipients: sodium chloride 9 g, water for injection up to 1 liter

    Description:Transparent, colorless or slightly yellowish liquid.
    Pharmacotherapeutic group:plasma-substituting agent
    ATX: & nbsp

    B.05.A.A   Blood plasma preparations and plasma-substituting drugs

    Pharmacodynamics:

    Blood substitute, hyperosmotic solution with osmolarity 0.34-0.37 mmol / kg. Provides plazmozameschayuschee, antishock, replenishing the volume of circulating blood and antiaggregant effect. Due to the high osmotic pressure exceeding the oncotic pressure of plasma proteins by 2.5 times, it causes active involvement of tissue fluid (20-25 ml per 1 g of polymer) and retains it in the vascular bed for a sufficiently long period. Eliminates violations of the system hemodynamics, restores the volume of circulating blood, raises blood pressure, eliminates spasm of peripheral vessels.The introduction has a positive effect on the normalization of the main indicators of the acid-base state and the gas composition of the blood. Increases the suspension resistance of blood, reduces its viscosity characteristics, has a pronounced antiadhesive and antiaggregant effect on platelets, helps to eliminate peripheral stasis and aggregation of erythrocytes, leads to improved rheological properties of blood, activation of microcirculation and increased tissue blood flow. Infusions reduce the risk of developing a syndrome of disseminated intravascular coagulation. Non-toxic, pyrogen-free.

    Pharmacokinetics:

    It is excreted mainly by the kidneys, during the first 24 hours, about 50% is eliminated, and after 3 days only trace concentrations are determined in the blood. A small part accumulates in the RES, where it is gradually cleaved with dextranases (acidic alpha-glucosidase) to dextrose (not a source of carbohydrate nutrition), which prevents deposition in the internal organs for a long time.

    Indications:

    - Hypovolemic shock (pronounced posthemorrhagic hypovolemia, blood loss during childbirth, as a result of ectopic pregnancy, etc.);

    - traumatic shock (operational shock);

    - burn shock;

    - compression syndrome;

    - septic shock;

    - shock due to intoxication;

    - disorders of microcirculation (capillary blood flow), rheological properties of blood;

    - preoperative and postoperative prevention of embolism;

    - prophylaxis of thrombophlebitis;

    - to fill the apparatus of artificial circulation (in certain proportions with blood).

    Contraindications:

    Hypersensitivity, cardiovascular insufficiency, ongoing internal bleeding, craniocerebral trauma, intracranial hypertension, hemorrhagic stroke, anuria, thrombocytopenia, clinical situations in which the introduction of large volumes of fluids is undesirable (including hypertension, hyperkalemia in the presence of hematocrit below 0.3), severe chronic renal failure.

    Carefully:

    Pronounced dehydration.

    Pregnancy and lactation:

    No data.

    Dosing and Administration:

    Intravenous, drip, with acute blood loss - intraarterially (in a hospital). The volume and speed of administration is determined by the patient's condition, blood pressure, heart rate, hematocrit.

    Transfusion is performed in the usual way, following the rules of transfusion: before transfusion biological test (after the administration of 5-10 drops, a 3-minute break is made, then another 10-15 drops are added and after another break, if there are no symptoms of the reaction (heart rate increase, blood pressure decrease, skin hyperemia, difficulty breathing), continue the transfusion).

    With developed shock or acute blood loss - intravenously, struino, 0.4-2 l (5-25 ml / kg). After increasing blood pressure to 80-90 mm Hg. usually pass to a drop introduction at a rate of 3-3.5 ml / min (60-80 cap / min). Possible intra-arterial route of administration (in the same dosages). Infusion of the drug should be carried out under constant control of the main indicators of systemic hemodynamics. With a significant increase in central venous pressure, reduce the dose and rate of administration or completely stop.

    With blood loss of more than 500-750 ml and severe anemia, the patient is combined with a blood transfusion, erythrocytic mass or red blood cell suspension necessary to eliminate tissue hypoxia, as well as fresh-frozen plasma containing hemostatic system factors.

    For the prevention of operational blood loss, as well as with the aim of achieving artificial hemodilution, preventing thrombosis and reducing the tendency to develop or progress the syndrome of desynvised intravascular coagulation the drug is administered in doses of 5-10 ml / kg (children - 10-15 ml / kg) for 30-60 minutes before surgery (in the case of a significant decrease in blood pressure go to the jet injection, with a drop in blood pressure below 60 mm Hg .- intra-arterially). The volume of infusion during surgery is determined by the magnitude of operational blood loss (hematocrit should not fall below 0.3).

    In the postoperative period rapid infusion is an effective way to prevent shock.

    With burn shock: in the first 24 hours, 2-3 liters are introduced, in the next 24 hours, 1.5 liters. Children in the first 24 hours - 40-50 ml / kg, the next day - 30 ml / kg.

    With extensive and deep burns combined with the introduction of plasma, albumin, gamma globulin; with burns more than 30-40% of the body surface - with blood transfusion.

    To prevent possible dehydration of tissues it is recommended to combine the infusion of the drug with the introduction of crystalloid solutions in a ratio of 1: 2.

    Side effects:Allergic reactions (hyperemia and itching of the skin, angioedema).
    Overdose:

    Perhaps an excessive increase in blood pressure, for the normalization of which peripheral vasodilators are administered.

    Interaction:

    Polyglucin can not be used as a solvent for other drugs (unfavorable physicochemical interactions are possible).

    It is allowed to use together with other widely used transfusion means.

    Special instructions:

    The drug can withstand freezing and can be transported at -10 ° C. Freezing of the preparation is not a contraindication to its use, provided the packaging is kept sealed.

    Patients with severe dehydration are required to restore fluid deficiency prior to administration of dextrans, the rate of their administration should not exceed 500 ml / h. The introduction of recommended doses practically does not affect the hemostasis system. Exceeding the recommended dose may prolong bleeding time.

    Against the background of dextrans induced hemodilution, a decrease in protein and hemoglobin concentration in the plasma is possible. The amount of dextrans to be administered should be calculated in such a way that it does not reduce the hemoglobin below 90 g / l (hematocrit 27%) for a longer or shorter time.

    The introduction of dextrans does not prevent the determination of the blood group and the conduct of a cross sample by standard methods (it is recommended to wash the erythrocytes with 0.9% solution of sodium chloride before the study). The presence of dextran in the blood can influence the results of enzymatic methods based on papain.

    In the investigation of blood glucose using solutions of sulfuric and acetic acids can be obtained glucose concentration greater than it actually is (the latter can be hydrolyzed dextran).

    Dextran reduces the transparency of blood, and its presence in the blood can change the results of measuring the concentration of bilirubin and protein. It is recommended to take blood samples to establish the concentration of bilirubin and protein before the injection of dextran.

    With the rapid introduction of dextrans in large volumes, it is possible to provoke the development of acute left ventricular failure and pulmonary edema.

    In the case of complaints of a feeling of tightness in the chest, difficulty breathing, low back pain, as well as chills, cyanosis, circulatory disturbance and breathing, transfusion should be stopped,IV infusion of 10 ml of 10% calcium chloride solution, 20 ml of 40% dextrose solution, antihistamines, glucocorticosteroid agents and appropriate symptomatic therapy.

    Form release / dosage:Solution for infusion, 6%.
    Packaging:

    100, 200 or 400 ml in glass bottles for blood, infusion and transfusion preparations with a capacity of 100, 250 or 450 ml respectively, sealed with rubber stoppers and crimped with aluminum caps.

    A label is labeled on the bottle with label paper, or coated paper, or writing paper.

    Each bottle, together with the instruction for use, is placed in a pack of cardboard for consumer containers.

    56 bottles with a capacity of 100 ml, 24, 28 bottles with a capacity of 250 ml or 12, 15 bottles with a capacity of 450 ml, respectively, are placed in boxes of corrugated cardboard with an enclosed instructions for use in an amount corresponding to the number of bottles (for hospitals).

    100, 200, 250, 400, 500 and 1000 ml into bags of a polyolefin film.

    For each package, a self-adhesive label is applied or the label text is applied to the package by hot stamping, using thermal printing.

    It is allowed to apply the text of the instructions for use directly to the package by hot stamping, thermal printing or a self-adhesive label.

    56 bags of 100 ml, 24, 28 packs of 200 ml or 250 ml, 12.15 packs of 400 ml or 500 ml, 12 packets of 1000 ml are placed in boxes of cardboard corrugated together with instructions for use in an amount corresponding to the number of packages (for hospitals).

    Storage conditions:

    In a dry place inaccessible to children, at a temperature of -10 to +20 ° C.

    Shelf life:

    5 years.

    After the expiry date, the drug should not be used.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-001462
    Date of registration:02.08.2011 / 17.08.2015
    The owner of the registration certificate:Promomed Rus, Open CompanyPromomed Rus, Open Company Russia
    Manufacturer: & nbsp
    Representation: & nbspBIOCHEMICAL JSC BIOCHEMICAL JSC Russia
    Information update date: & nbsp10.01.2016
    Illustrated instructions
      Instructions
      Up